Xofigo

Important Coding, Purchasing, and Reimbursement Changes for Xofigo® (radium Ra 223 dichloride) Injection Effective January 1, 2015

Nivolumab

On December 22, 2014, the U. S. Food and Drug Administration granted accelerated approval to nivolumab (OPDIVO, Bristol-Myers Squibb Company) for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if...